Gene Therapy Market

Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024

Report Code: BT 7506 Jan, 2020, by marketsandmarkets.com
COVID-19

Get in-depth analysis of the COVID-19 impact on the Gene Therapy Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Gene Therapy Market

Request For Special Pricing

[135 Pages Report] The global gene therapy market is estimated to grow from USD 3.8 billion in 2019 to USD 13.0 billion by 2024, at a CAGR of 27.8%. The growth of this market is majorly driven by the high incidence of cancer and other target diseases, availability of reimbursements, and the increasing funding for gene therapy research. However, the high cost of gene therapies is expected to hamper market growth to a certain extent during the forecast period.

Gene Therapy Market

The demand for gene therapies for the treatment of cancer is estimated to grow at a high rate during the forecast period

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the approval of a growing number of gene therapies for the treatment of cancer and the rising incidence of hematologic cancers.

Non-viral vectors segment accounted for the largest share of the gene therapy market, by vector, in 2018

The market, by vector, has been segmented into viral and non-viral vectors. The non-viral vectors segment accounted for the largest share of the market in 2018. This can be attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

Gene Therapy Market

North America is the largest regional market for gene therapies

The global market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. The rising prevalence of chronic diseases, high and growing healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of major market players in the region are the major factors driving the growth of the gene therapy market in North America.

Key Market Players

The prominent players operating in the gene therapy market include Biogen (US), Novartis AG (Switzerland), Gilead Sciences, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Italy), Orchard Therapeutics plc. (UK), SIBIONO (China), Shanghai Sunway Biotech Co., Ltd. (China), bluebird bio, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals, Inc. (Ireland), Akcea Therapeutics (US), and Dynavax Technologies (US).

Biogen was the leading player in the market in 2018. Strong business operations across all key regions, coupled with a strong brand image, have made Biogen a leading player in this market. Biogen adopted organic and inorganic growth strategies, such as agreements & collaborations and acquisitions, to maintain its leading position in the market. For instance, in 2017, Biogen entered into a collaboration with Ionis Pharmaceuticals to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy. In 2019, the company received the NMPA (National Medical Products Association) approval in China for SPINRAZA, which is used for treating 5q spinal muscular atrophy.

Scope of the Report

Report Metric

Details

Market size available for years

2017–2024

Base year considered

2018

Forecast period

2019–2024

Forecast units

Value (USD)

Segments covered

Indication, vector, delivery method, and region

Geographies covered

North America, Europe, the Asia Pacific, and the Rest of the World

Companies covered

Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Italy), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

This report categorizes the market into the following segments and subsegments:

  • Vector
    • Non-viral vectors
      • Oligonucleotides
      • Other non-viral vectors (plasmids and RNAi)
  • Viral vectors
    • Retroviral vectors
      • Gammaretroviral vectors
      • Lentiviral vectors
    • Adeno-associated virus vectors
    • Other viral vectors (herpes simplex and adenoviral vectors)
  • Indication
    • Neurological diseases
    • Cancer
    • Duchenne muscular dystrophy
    • Hepatological diseases
    • Other indications (retinal diseases, beta-thalassemia, peripheral artery disease, and immune deficiency diseases)
  • Delivery method
    • In vivo
    • Ex vivo
  • Region
    • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments

  • In May 2019, Novartis AG (Switzerland) received FDA approval for ZOLGENSMA.
  • In June 2019, Biogen (US) acquired Nightstar Therapeutics (UK) to enhance its presence in the market.
  • In June 2018, Amgen (US) collaborated with the University of Texas MD Anderson Cancer Center (US) to develop a variety of Amgen's early-stage oncology therapies.

Key Questions Addressed by the Report

  • Where will all these developments take the industry in the mid-to-long term?
  • What are the recent trends affecting the market?
  • Who are the key players in the market, and how intense is the competition?
  • What are the key indications of gene therapy?
  • Which region is lucrative for the market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 16)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 19)
    2.1 RESEARCH DATA
    2.2 SECONDARY DATA
           2.2.1 SECONDARY SOURCES
    2.3 PRIMARY DATA
    2.4 MARKET SIZE ESTIMATION
           2.4.1 BOTTOM-UP APPROACH
           2.4.2 BOTTOM-UP APPROACH FOR THE NON-VIRAL VECTORS AND VIRAL VECTORS MARKET
           2.4.3 GROWTH FORECAST
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 25)

4 PREMIUM INSIGHTS (Page No. - 28)
    4.1 GENE THERAPY MARKET OVERVIEW
    4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2018)
    4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET

5 MARKET OVERVIEW (Page No. - 30)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 High incidence of cancer and other target diseases
                    5.2.1.2 Product approvals
                    5.2.1.3 Funding for gene therapy research
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Strong product pipeline
           5.2.3 CHALLENGES
                    5.2.3.1 High cost of treatments

6 GENE THERAPY MARKET, BY VECTOR (Page No. - 35)
    6.1 INTRODUCTION
    6.2 NON-VIRAL VECTORS
           6.2.1 OLIGONUCLEOTIDES
                    6.2.1.1 Oligonucleotides accounted for the largest share of the non-viral vectors market
           6.2.2 OTHER NON-VIRAL VECTORS
    6.3 VIRAL VECTORS
           6.3.1 RETROVIRAL VECTORS
                    6.3.1.1 Gamma-retroviral vectors
                               6.3.1.1.1 Availability of a wide range of gamma-retroviral vectors supporting market growth
                    6.3.1.2 Lentiviral vectors
                               6.3.1.2.1 North America accounted for the largest share of the lentiviral vectors market
           6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
                    6.3.2.1 Possible use in in vivo applications has driven interest in adeno-associated virus vectors
           6.3.3 OTHER VIRAL VECTORS

7 GENE THERAPY MARKET, BY INDICATION (Page No. - 44)
    7.1 INTRODUCTION
    7.2 NEUROLOGICAL DISEASES
           7.2.1 NEUROLOGICAL DISEASES FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
    7.3 CANCER
           7.3.1 DEMAND FOR GENE THERAPIES FOR THE TREATMENT OF CANCER TO GROW AT A HIGH RATE
    7.4 HEPATOLOGICAL DISEASES
           7.4.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS WILL SUPPORT MARKET GROWTH
    7.5 DUCHENNE MUSCULAR DYSTROPHY
           7.5.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
    7.6 OTHER INDICATIONS

8 GENE THERAPY MARKET, BY DELIVERY METHOD (Page No. - 49)
    8.1 INTRODUCTION
    8.2 IN VIVO GENE THERAPY
           8.2.1 IN VIVO GENE THERAPY SEGMENT TO DOMINATE THE MARKET
    8.3 EX VIVO GENE THERAPY
           8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD

9 GENE THERAPY MARKET, BY REGION (Page No. - 53)
    9.1 INTRODUCTION
    9.2 NORTH AMERICA
           9.2.1 US
                    9.2.1.1 The US dominates the global gene therapy market
           9.2.2 CANADA
                    9.2.2.1 Growing burden of cancer will support market growth in Canada
    9.3 EUROPE
           9.3.1 GERMANY
                    9.3.1.1 Germany accounted for the largest share of the market in Europe
           9.3.2 FRANCE
                    9.3.2.1 Increasing cancer incidence to support market growth
           9.3.3 UK
                    9.3.3.1 Rising incidence of melanoma will support market growth in the UK
           9.3.4 ITALY
                    9.3.4.1 High incidence of targeted diseases and increasing per capita healthcare spending will drive market growth in Italy
           9.3.5 SPAIN
                    9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
           9.3.6 REST OF EUROPE
    9.4 ASIA PACIFIC
           9.4.1 JAPAN
                    9.4.1.1 Japan dominates the APAC market for gene therapy
           9.4.2 CHINA
                    9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
           9.4.3 REST OF ASIA PACIFIC
    9.5 REST OF THE WORLD

10 COMPETITIVE LANDSCAPE (Page No. - 89)
     10.1 OVERVIEW
     10.2 MARKET SHARE ANALYSIS, 2018
     10.3 KEY STRATEGIES
     10.4 COMPETITIVE LEADERSHIP MAPPING (2018)
             10.4.1 VISIONARY LEADERS
             10.4.2 INNOVATORS
             10.4.3 DYNAMIC DIFFERENTIATORS
             10.4.4 EMERGING COMPANIES

11 COMPANY PROFILES (Page No. - 95)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     11.1 BIOGEN
     11.2 SAREPTA THERAPEUTICS
     11.3 GILEAD SCIENCES, INC.
     11.4 AMGEN, INC.
     11.5 NOVARTIS AG
     11.6 ORCHARD THERAPEUTICS PLC
     11.7 SPARK THERAPEUTICS, INC. (A PART OF ‎F. HOFFMANN-LA ROCHE)
     11.8 MOLMED S.P.A.
     11.9 ANGES, INC.
     11.10 BLUEBIRD BIO, INC.
     11.11 JAZZ PHARMACEUTICALS PLC
     11.12 DYNAVAX TECHNOLOGIES
     11.13 HUMAN STEM CELLS INSTITUTE
     11.14 SIBIONO GENETECH CO., LTD.
     11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
     11.16 UNIQURE N.V.
     11.17 GENSIGHT BIOLOGICS S.A.
     11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
     11.19 CELLECTIS
     11.20 SANGAMO THERAPEUTICS
     11.21 MUSTANG BIO
     11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
     11.23 POSEIDA THERAPEUTICS, INC.

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 129)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS


LIST OF TABLES (127 Tables)

TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 2 PRODUCT APPROVALS, 2015–2019
TABLE 3 GENE THERAPY MARKET: LIST OF SOME PIPELINE DRUGS
TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2018
TABLE 5 GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 6 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 7 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 8 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2017–2024 (USD MILLION)
TABLE 9 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 10 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 11 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 12 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 13 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 14 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 15 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 16 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 17 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2017–2024 (USD MILLION)
TABLE 18 GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 19 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 20 NUMBER OF CANCER PATIENTS, BY TYPE, 2012–2030
TABLE 21 GENE THERAPY MARKET FOR CANCER, BY REGION, 2017–2024 (USD MILLION)
TABLE 22 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 2017–2024 (USD MILLION)
TABLE 23 GENE THERAPY MARKET FOR DMD, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 25 GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 26 IN VIVO GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 27 EX VIVO GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 28 GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 31 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 32 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 33 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 35 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 36 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
TABLE 37 US FDA GENE THERAPY PRODUCT APPROVALS
TABLE 38 US: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 39 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 40 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 41 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 42 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 43 US: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 44 CANADA: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 45 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 46 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 47 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 48 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 49 CANADA: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 52 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 53 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 54 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 55 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 56 EUROPE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 57 GERMANY: INCIDENCE OF HEMATOLOGIC CANCERS, BY TYPE, 2018 VS. 2025
TABLE 58 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 59 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 61 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 62 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 63 GERMANY: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 64 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 65 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 66 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 67 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 69 FRANCE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 70 UK: INCIDENCE OF CANCERS, BY TYPE, 2018 VS. 2025
TABLE 71 UK: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 72 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 73 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 74 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 76 UK: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 77 ITALY: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 78 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 79 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 80 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 82 ITALY: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 83 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 84 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 86 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 87 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 88 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 89 ROE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 90 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 92 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 94 ROE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 95 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 96 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 97 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 98 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 99 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 100 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 101 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 102 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 103 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 104 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 105 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 106 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 107 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 108 CHINA: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 109 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 110 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 111 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 112 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 113 CHINA: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 114 REST OF APAC: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 115 REST OF APAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116 REST OF APAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117 REST OF APAC: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 118 REST OF APAC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 119 REST OF APAC: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 120 ROW: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 121 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 122 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 123 ROW: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 124 PRODUCT APPROVALS, 2016–2019
TABLE 125 ACQUISITIONS, 2016–2019
TABLE 126 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS, 2016–2019
TABLE 127 EXPANSIONS, 2016–2019
 
 
LIST OF FIGURES (25 Figures)
 
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 DATA TRIANGULATION METHODOLOGY
FIGURE 4 GENE THERAPY MARKET, BY VECTOR, 2019 VS. 2024 (USD MILLION)
FIGURE 5 GENE THERAPY MARKET, BY DELIVERY METHOD, 2019 VS. 2024 (USD MILLION)
FIGURE 6 GENE THERAPY MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 7 GENE THERAPY MARKET: REGIONAL SNAPSHOT
FIGURE 8 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
FIGURE 9 NON-VIRAL VECTORS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN GENE THERAPY MARKET IN 2018
FIGURE 10 COUNTRIES IN NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 11 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12 NON-VIRAL VECTORS SEGMENT WILL CONTINUE TO DOMINATE THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
FIGURE 13 IN VIVO GENE THERAPY SEGMENT WILL CONTINUE TO DOMINATE THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
FIGURE 14 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
FIGURE 15 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
FIGURE 16 GENE THERAPY MARKET SHARE ANALYSIS, 2018
FIGURE 17 VENDOR COMPARISON MATRIX: GENE THERAPY MARKET
FIGURE 18 BIOGEN: COMPANY SNAPSHOT
FIGURE 19 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
FIGURE 20 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
FIGURE 21 AMGEN, INC.: COMPANY SNAPSHOT
FIGURE 22 NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 23 SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
FIGURE 24 ANGES, INC.: COMPANY SNAPSHOT
FIGURE 25 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT

This study involved four major activities in estimating the current size of the gene therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. The bottom-up approach was employed to estimate the size of the market. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

Secondary research was mainly used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the gene therapy market. The secondary sources used for this study include the World Health Organization (WHO), American Cancer Society, GLOBOCAN, Centers for Disease Control and Prevention, American Society of Gene & Cell Therapy, National Center for Biotechnology Information, European Journal of Human Genetics, Organisation for Economic Co-operation and Development, Annual Reports, Press Releases, SEC Filings, and Investor Presentations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Gene Therapy Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the gene therapy market have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size, using the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global gene therapy market on the basis of indication, vector, delivery method, and region
  • To provide detailed information regarding the major factors influencing the growth of this market (such as drivers, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World
  • To profile key market players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions; new product launches; expansions; agreements, partnerships, and collaborations; and R&D activities in the market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per a company’s specific needs. The following customization options are available for this report:

Country Information

  • Gene therapy market size and growth rate estimates for counties in the Rest of Europe

Company profiles

  • Profiles of five additional companies operating in the market
Report Code
BT 7506
Published ON
Jan, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Gene Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home